Skip Nav Destination
1-20 of 168
Keywords: Multiple myelomaClose
Acta Haematol 1–5.
Published Online: 20 June 2023
... allows the generation of multi-energy images with increased contrast and scanning speed or ultra-high spatial resolution (UHR) images with lower radiation doses, compared to the currently used energy integrating detector (EID) CT. Since the recognition of bone disease related to multiple myeloma...
Salvatore Troisi, Valentina Giudice, Mario Troisi, Denise Morini, Andrea Crudele, Bianca Cuffa, Carmine Selleri, Bianca Serio
Acta Haematol 1–7.
Published Online: 16 June 2023
...Salvatore Troisi; Valentina Giudice; Mario Troisi; Denise Morini; Andrea Crudele; Bianca Cuffa; Carmine Selleri; Bianca Serio Daratumumab, an anti-CD38 monoclonal antibody, is worldwide approved for treatment of newly diagnosed and relapsed/refractory multiple myeloma (MM) patients and is available...
Acta Haematol (2023) 146 (2): 125–136.
Published Online: 20 April 2023
...Kazuhito Suzuki; Morio Matsumoto; Yasushi Hiramatsu; Naoki Takezako; Yotaro Tamai; Kenshi Suzuki Introduction: Elotuzumab and lenalidomide plus dexamethasone (ERd) is a standard salvage chemotherapy for multiple myeloma, and elotuzumab is commonly administered every 2 weeks after cycle 3...
Andrea Duminuco, Alessandra Romano, Elena Sabattini, Loredana Villari, Vittorio Del Fabro, Federica Elia, Giuseppe A. Palumbo, Francesco Di Raimondo, Concetta Conticello
Acta Haematol (2023) 146 (4): 331–337.
Published Online: 17 April 2023
...) and lymphoproliferative disorders, such as lymphomas. Instead, since the association with plasma cell diseases such as multiple myeloma and plasmacytoma is infrequent, there is a lack of literature. This manuscript aimed to revise the literature by describing a rare case of CD and plasmacytoma and attempting to explain...
Tamar Berger, Adi Shacham Abulafia, Shai Shimony, Oren Pasvolsky, Iuliana Vaxman, Yifat Miron, Shimrit Feldman, Avi Leader, Pia Raanani
Acta Haematol (2022) 145 (6): 619–626.
Published Online: 29 July 2022
... multiple myeloma (SMM, n = 2) and low-risk monoclonal gammopathy of undetermined significance (MGUS, n = 6). Six patients were on tyrosine kinase inhibitor treatment, 2 were in treatment-free remission. The only covariate associated with paraproteinemia was the presence of anemia, albeit with borderline...
Yosuke Okada, Masahiro Teramoto, Noriaki Tachi, Toshikuni Kawamura, Toshikatsu Horiuchi, Shoichiro Kato, Takaaki Maekawa, Yukiko Osawa, Shinichi Kobayashi, Fumihiko Kimura
Acta Haematol (2022) 145 (6): 582–591.
Published Online: 11 January 2022
... and prognostic value of multiple myeloma (MM). MYC gene-related abnormalities (MYC GAs) are one of the CAs, but their unfavorable impact has not been fully investigated in daily clinical practice. Methods: This study retrospectively analyzed the prognostic impact of MYC GAs on 81 patients through fluorescence...
Acta Haematol (2022) 145 (3): 326–333.
Published Online: 24 November 2021
...Josefin Hidman; Anders Larsson; Måns Thulin; Torbjörn Karlsson Introduction: In multiple myeloma, there is an increase in bone marrow microvascular density and enhanced renal lymphangiogenesis. Increased levels of the proangiogenic protein growth differentiation factor-15 (GDF15) have previously...
Acta Haematol (2021) 144 (5): 542–550.
Published Online: 30 March 2021
...Congyang Huang; Hanshan Liu; Li Jia; Min Lu; Suyun Hu Background/Aim: The impacts of health insurance status on survival outcomes in multiple myeloma (MM) have not been addressed in depth. The present study was conducted to identify definite relationships of cancer-specific survival (CSS...
Hareth Nahi, Göran Walinder, Vishal Patel, Ying Qu, Aaron Levine, Istvan Majer, Lucie Kutikova, Eva Hellqvist Franck, Maria K. Svensson, Markus Hansson
Acta Haematol (2021) 144 (5): 519–527.
Published Online: 25 February 2021
...Hareth Nahi; Göran Walinder; Vishal Patel; Ying Qu; Aaron Levine; Istvan Majer; Lucie Kutikova; Eva Hellqvist Franck; Maria K. Svensson; Markus Hansson Introduction: Treatment-induced peripheral neuropathy (TIPN) is a complication of multiple myeloma (MM) treatment. Objective: This real-world...
Kenshi Suzuki, Kazutaka Sunami, Morio Matsumoto, Akio Maki, Fumika Shimada, Kazuyuki Suzuki, Kazuyuki Shimizu
Acta Haematol (2021) 144 (3): 264–274.
Published Online: 04 December 2020
... study in relapsed/refractory multiple myeloma (MM). Here, we present data from a phase II study (NCT02290431) of this combination in Japanese patients with relapsed or relapsed-and-refractory MM. Methods: Patients received 3-week cycles of 20-mg oral panobinostat (weeks 1 and 2), 1.3-mg/m 2 subcutaneous...
Laura Notarfranchi, Valentina Marchica, Benedetta Dalla Palma, Laura Pelagatti, Jessica Burroughs-Garcia, Mario Pedrazzoni, Livia Ruffini, Filomena Cetani, Claudio Marcocci, Nicola Giuliani
Acta Haematol (2021) 144 (3): 302–307.
Published Online: 09 September 2020
...Laura Notarfranchi; Valentina Marchica; Benedetta Dalla Palma; Laura Pelagatti; Jessica Burroughs-Garcia; Mario Pedrazzoni; Livia Ruffini; Filomena Cetani; Claudio Marcocci; Nicola Giuliani Hypercalcemia is a significant feature of patients with active multiple myeloma (MM) with extensive bone...
Acta Haematol (2021) 144 (3): 252–258.
Published Online: 13 July 2020
... between ESA and glucose in anemia-treated patients with myelodysplastic syndromes (MDS) or multiple myeloma (MM). Patients and Methods: Patients’ glucose levels were compared while on to while off ESA, and all served as their own controls. To test the association between ESA and blood glucose, we employed...
Acta Haematol (2020) 143 (6): 559–566.
Published Online: 01 July 2020
...Yang Liu; Lei Wen; Huan Chen; Yao Chen; Wenbing Duan; Ying Kang; Ling Ma; Xiaojun Huang; Jin Lu Background: Serum lactate dehydrogenase (LDH) is an adverse prognostic factor for newly diagnosed multiple myeloma (MM). However, the role of LDH in the prognosis of MM patients with relapse has not yet...
Acta Haematol (2020) 143 (5): 410–416.
Published Online: 17 April 2020
...Abdullah S. Al Saleh; Taimur Sher; Morie A. Gertz We provide our recommendations (not evidence based) for managing multiple myeloma patients during the pandemic of COVID-19. We do not recommend therapy for smoldering myeloma patients (standard or high risk). Screening for COVID-19 should be done...
Acta Haematol (2020) 143 (2): 118–123.
Published Online: 31 March 2020
... and immunotherapy is increasingly recognized. Plasma cells in multiple myeloma have the potential to survive in the gastrointestinal tract for long periods of time. The nature of the gut microbiota impacts the degree of antigen stimulation of these cells and may play a role in mutation development and clonal...
Iván Murrieta-Álvarez, David P. Steensma, Juan Carlos Olivares-Gazca, Mauricio Olivares-Gazca, Andrés León-Peña, Yahveth Cantero-Fortiz, Yarely Itzayana García-Navarrete, Antonio Cruz-Mora, Alejandro Ruiz-Argüelles, Guillermo José Ruiz-Delgado, Guillermo José Ruiz-Argüelles
Acta Haematol (2020) 143 (6): 552–558.
Published Online: 11 February 2020
...: The treatment of patients with multiple myeloma (MM) has evolved in recent years, and the disease-associated prognosis has improved substantially. This improvement has been driven largely by the approval of novel agents, many of which are expensive and not universally available. Less expensive but effective...
Ling-Juan Huang, Ying Shen, Ju Bai, Fang-Xia Wang, Yuan-Dong Feng, Hong-Li Chen, Yue Peng, Ru Zhang, Fang-Mei Li, Pei-Hua Zhang, Xiao-Ru Lei, Feng Xue, Yan-Ping Ma, Jin-Song Hu, Ai-Li He
Acta Haematol (2020) 143 (3): 279–288.
Published Online: 09 October 2019
... gene 18 ( SNHG18 ) andsemaphorin 5A ( SEMA5A ) genes in multiple myeloma (MM) patients and to explore the correlation of the expression of these genes with the clinical characteristics and prognosis of MM patients. Methods: Forty-seven newly diagnosed MM, 18 complete remission MM, 13 refractory/relapse...
Acta Haematol (2019) 142 (4): 208–216.
Published Online: 04 June 2019
...Pu Xiang; Yuzhang Liu; Lina Liu; Quande Lin; Xiyang Liu; Hongmei Zhang; Jie Xu; Baijun Fang Background: miR-886-5p plays an important role in many tumors, but it has been rarely investigated in multiple myeloma (MM). We studied the expression of miR-886-5p in the plasma of MM patients and in MM...
Keisuke Tanaka, Shigeo Toyota, Megumi Akiyama, Naoki Wakimoto, Yuichi Nakamura, Yuho Najima, Noriko Doki, Kazuhiko Kakihana, Aiko Igarashi, Takeshi Kobayashi, Kazuteru Ohashi, Daisuke Kudo, Atsushi Shinagawa, Hina Takano, Takayuki Fujio, Yasushi Okoshi, Mitsuo Hori, Takashi Kumagai, Tatsuya Saito, Junichi Mukae, Koh Yamamoto, Ikuyo Tsutsumi, Takuya Komeno, Chikashi Yoshida, Masahide Yamamoto, Hiroshi Kojima, on behalf of the Ochanomizu Hematology Study Group
Acta Haematol (2019) 141 (2): 111–118.
Published Online: 06 February 2019
... transplantation (ASCT) in newly diagnosed Japanese patients with multiple myeloma (MM). This regimen consisted of four 28-day cycles of once-weekly oral cyclophosphamide (300 mg/m 2 ), subcutaneous bortezomib (1.3 mg/m 2 ), and oral dexamethasone (40 mg). Responding patients underwent stem cell collection...
Fabián Tarín, Francisco López-Castaño, Carmen García-Hernández, Paola Beneit, Héctor Sarmiento, Pablo Manresa, Olga Alda, Blanca Villarrubia, Margarita Blanes, Javier Bernabéu, Carmen Amorós, Sara Sánchez-Sánchez, Carmen Fernández-Miñano, Francisco De Paz, José Verdú-Belmar, Pascual Marco, Estella Matutes
Acta Haematol (2019) 141 (1): 1–6.
Published Online: 15 January 2019
... Matutes Multiparameter flow cytometry (MFC)-based clonality assessment is a powerful method of diagnosis and follow-up in monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM). However, the relevance of intraclonal heterogeneity in immunophenotypic studies remains poorly...